New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction.
OBJECTIVE
Treatment of metastatic colorectal cancer with new drugs (NDs) as oxaliplatin and irinotecan had improved response and survival. In order to check whether the promising achievements of the trials are obtained in routine clinical practice, we have reviewed retrospectively our results for two periods, before (period A: 1993-1995, n=63) and after (period B:1998-2000 n=103) the introduction of these NDs. Patients characteristics, treatment modalities, survival, and prognostic factors were compared.


METHODS
There were 74 women and 92 men, aged 60.8+/-11.6 yr, 7 patients received best supportive care only, 91 had synchronous metastasis.


RESULTS
Period B patients were older, with WHO score>1 more often, more adjuvant treatment, more metachronous metastasis, and NDs used more frequently (24% vs 59%). Median survival was similar (16 vs 15 mo). But when looking at the population aged<75 years with WHO score<2, median survival was 13 mo (period A) vs 21 mo (period B); survival at 1, 2, and 3 yr were respectively 59.5+/-8%, 16.2+/-6 %, 13.5+/-6 % vs 69.8+/-6%, 49.6+/-7%, 29.8+/-7%, p<0.01). In multiparametric analysis, factors correlated with survival were the absence of elevated serum alkaline phosphatase, a unique metastatic organ, and administration of NDs.


CONCLUSIONS
In our routine clinical experience the use of NDs for metastatic CRC has allowed a significant improvement in survival among patients with unresectable tumors.
Egreteau
Joëlle
J
Oncologie Médicale, Centre Eugène Marquis, 35042 - Rennes France.
Boucher
Eveline
E
de Guibert
Sophie
S
Jacquelinet
Christian
C
Meunier
Bernard
B
Boudjema
Karim
K
Raoul
Jean-Luc
JL
D000367:Age Factors; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008495:Medical Oncology / Q000706:statistics & numerical data; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D011799:Quinazolines; D013876:Thiophenes; D000077150:Oxaliplatin; D000077146:Irinotecan; C068874:raltitrexed; D002166:Camptothecin
Ann Oncol. 2003;14 Suppl 2:ii13-6
12810452
Br Med Bull. 2002;64:127-40
12421730
J Clin Oncol. 1997 Feb;15(2):808-15
9053508
Eur J Cancer. 1993;29A(9):1280-4
8343268
Lancet. 1998 Oct 31;352(9138):1413-8
9807987
Br J Cancer. 1998;77 Suppl 2:15-21
9579851
J Clin Oncol. 2004 Jan 15;22(2):229-37
14657227
J Clin Oncol. 1989 Apr;7(4):425-32
2926468
Semin Oncol. 2002 Oct;29(5 Suppl 15):3-10
12422303
J Clin Oncol. 1998 Apr;16(4):1470-8
9552054
Lancet. 2000 Mar 25;355(9209):1041-7
10744089
Ann Surg. 2000 Apr;231(4):487-99
10749608
Ann Oncol. 1999 Jun;10(6):663-9
10442188
BMJ. 1993 Mar 20;306(6880):752-5
7683942
J Clin Oncol. 2000 Aug;18(16):2938-47
10944126
J Clin Oncol. 1992 Jun;10(6):896-903
1534121
Arch Surg. 1997 May;132(5):505-10; discussion 511
9161393